KLOR-CON M20
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KLOR-CON M20 (KLOR-CON M20).
Potassium is the major intracellular cation; it is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of acid-base balance. Potassium replacement therapy corrects hypokalemia.
| Metabolism | Potassium is not metabolized; it is excreted primarily by the kidneys. |
| Excretion | Potassium is primarily excreted renally (approximately 90%) as potassium ion in urine. A small amount is excreted in feces (about 10%). |
| Half-life | The terminal elimination half-life of potassium is approximately 8-12 hours in healthy individuals, but is prolonged in renal impairment. |
| Protein binding | Potassium is not significantly bound to plasma proteins; protein binding is negligible (<5%). |
| Volume of Distribution | The volume of distribution for potassium is approximately 0.4-0.6 L/kg, reflecting its distribution primarily in the extracellular fluid compartment. |
| Bioavailability | Oral potassium chloride is well absorbed, with bioavailability of about 80-90% from the gastrointestinal tract. |
| Onset of Action | Oral potassium chloride (Klor-Con M20) produces a measurable increase in serum potassium within 1-2 hours, with peak effect at 4-6 hours. |
| Duration of Action | The duration of action for a single dose is typically 6-8 hours, but sustained-release formulations like Klor-Con M20 provide extended release over 8-12 hours. |
20 mEq potassium chloride orally once daily, adjusted based on serum potassium levels and patient response. Maximum rate of administration: 20 mEq per hour if intravenous; oral doses divided if >20 mEq per dose.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | GFR 30-50 mL/min: reduce dose by 25-50% or monitor serum potassium closely. GFR <30 mL/min: avoid use due to risk of hyperkalemia; use only if potassium-depleted and with extreme caution. For patients on dialysis: 40-80 mEq/day may be needed, but monitor potassium levels frequently. |
| Liver impairment | Child-Pugh Class A: no adjustment. Class B: initiate at 50% of standard dose and titrate cautiously. Class C: avoid use or use with extreme caution and close monitoring of serum potassium, as hepatic encephalopathy may be exacerbated. |
| Pediatric use | Potassium deficiency: 1-4 mEq/kg/day orally in divided doses, not to exceed 1 mEq/kg as a single dose. Maximum single dose: 20 mEq. For intravenous replacement: 0.5-1 mEq/kg/hour with continuous ECG monitoring, maximum 3 mEq/kg/day. Use only with close monitoring of serum potassium and renal function. |
| Geriatric use | Start at lower end of adult dosing (e.g., 10-20 mEq/day) due to age-related decline in renal function. Monitor serum potassium and renal function every 1-2 weeks during initiation. Avoid sustained-release formulations in patients with delayed GI transit; use immediate-release if needed. Maximum rate of intravenous administration: 10 mEq/hour in elderly to avoid hyperkalemia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for KLOR-CON M20 (KLOR-CON M20).
| Breastfeeding | Potassium is a normal component of breast milk, and potassium chloride supplementation is generally considered compatible with breastfeeding. The M/P ratio is approximately 0.4-0.6, indicating low transfer. No adverse effects in breastfed infants have been reported. However, monitor maternal serum potassium to avoid excess. |
| Teratogenic Risk | Potassium chloride is considered low risk for teratogenicity. No increased risk of major congenital malformations has been observed in human studies. However, maternal hypokalemia or hyperkalemia secondary to potassium supplementation may pose fetal risks. First trimester: No evidence of teratogenicity. Second and third trimesters: Maternal electrolyte disturbances may affect fetal development. Peripartum: Maternal hyperkalemia can cause neonatal arrhythmias. |
■ FDA Black Box Warning
Potassium chloride extended-release capsules must be administered with caution and under close monitoring in patients with impaired renal function or other conditions that predispose to hyperkalemia. The use of potassium chloride supplements is contraindicated in patients with severe renal impairment, untreated Addison's disease, or acute dehydration. Do not break, crush, or chew the capsules. Stop therapy and evaluate if severe ulceration or stricture of the esophagus, stomach, or small bowel occurs.
| Serious Effects |
["Hyperkalemia (serum potassium >5.0 mEq/L)","Severe renal impairment with oliguria or anuria","Untreated Addison's disease","Acute dehydration","Heat cramps","Concomitant use with potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride)","Solid oral dosage forms in patients with esophageal compression or delayed GI transit"]
| Precautions | ["Hyperkalemia risk: Monitor serum potassium levels frequently, especially in patients with renal impairment, diabetes, or who are on potassium-sparing diuretics or ACE inhibitors.","Gastrointestinal adverse events: Esophageal ulceration, stricture, or perforation; use with caution in patients with esophageal compression or delayed GI transit.","Solid oral dosage forms may cause gastrointestinal lesions; consider liquid or powder formulations in patients with swallowing difficulties.","Do not use in patients with severe renal impairment (CrCl <30 mL/min) or anuria.","May cause metabolic acidosis; monitor acid-base status."] |
Loading safety data…
| Fetal Monitoring | Monitor serum potassium levels regularly, especially in patients with renal impairment or those on concurrent medications affecting potassium (e.g., ACE inhibitors, ARBs, potassium-sparing diuretics). Assess renal function periodically. Fetal monitoring: Standard prenatal care with ultrasound for fetal growth and amniotic fluid volume if maternal condition requires close monitoring. |
| Fertility Effects | No known adverse effects on fertility. Potassium supplementation is used to correct hypokalemia, which can improve overall health and may indirectly benefit reproductive function. No direct impact on gamete production or implantation has been reported. |